The Leukemia & Lymphoma Society CML-Expert Information About Diagnosis and Treatment
WHITE PLAINS, N.Y., Oct. 11, 2011 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is committed to bringing the most current information about blood cancers to all patients and is pleased to announce a unique educational opportunity for Spanish-speaking patients with chronic myeloid leukemia (CML). On Tuesday, October 25 from 1:00 to 2:00 PM eastern time, international CML expert Dr. Michael J. Mauro from Knight Cancer Institute at Oregon Health & Science University will present a free, live telephone/web education program titled CMLExpert Information About Diagnosis and Treatment. This program will be presented simultaneously in Spanish.
Each year, approximately 4,800 new cases of CML are diagnosed in the United States. CML is a blood cancer characterized by a specific chromosomal abnormality called the Philadelphia chromosome. Since the advent of targeted therapies, survival and quality of life for patients with CML has dramatically improved. In 2010, the U.S. Food and Drug Administration approved two new targeted therapies for the treatment of newly diagnosed CML. During the program on October 25, Dr. Mauro will discuss CML treatment options, as well as the critical importance of treatment adherence and monitoring of treatment response so that all patients may benefit fully from the advances made in CML therapy over the last 10 years. This program, offered by The Leukemia & Lymphoma Society, is supported by educational grants from Bristol-Myers Squibb and Novartis Oncology and offers continuing education credit for nurses and social workers.
To register for the October 25 program CML Expert Information About Diagnosis and Treatment in Spanish, please visit www.LLS.org/leukemiaeducationsp.
To register for CML Expert Information About Diagnosis and Treatment in English, please visit www.LLS.org/programs.
For information on other LLS programs, please visit www.LLS.org or contact an Information Specialist at (800) 955-4572.
SOURCE The Leukemia & Lymphoma Society